Safety and Tolerability
TRAEs
ADVERSE EVENTS, ADVERSE EVENT, HYPERBILIRUBINEMIA, DUODENAL ULCER HEMORRHAGE
There were no new safety signals identified with tivozanib. Treatment-related adverse events (TRAEs) occurred in 31 (67%) patients receiving tivozanib (Most common (>5% incidence) treatment-related adverse events.No grade 5 TRAEs occurred during this study. Two grade 4 TRAEs (duodenal ulcer hemorrhage, hyperbilirubinemia) occurred once in a single patient.Abbreviation: TRAE, treatment-related adverse event.